ReviewWorld journal of stem cells2021
Stem cell therapy for heart failure: Medical breakthrough, or dead end?
Review in World journal of stem cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Randomized comparison of the effects of tailored text messaging versus pillbox organizers on medication adherence of heart failure patients.BMC cardiovascular disorders · 2024Trial
- The promise of organ rejuvenation to overcome the shortage in organ transplantation.Nature communications · 2025Review
- A comprehensive review of clinical trials and Progress in stem cell therapies for advanced heart failure.Regenerative therapy · 2025Review
- The role of Mir-365-5p in regulating NF2-Mediated apoptosis and ROS production in hypoxic cardiomyoblasts.Molecular biology reports · 2025Article
- Stem Cell Therapy in Ischemic Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Injectable myocardium-derived hydrogels with SDF-1α releasing for cardiac repair.Biomaterials advances · 2025Article
- Cardiac Repair and Clinical Outcomes of Stem Cell Therapy in Heart Failure: A Systematic Review and Meta-Analysis.Diseases (Basel, Switzerland) · 2025Review
- Innovative approaches to boost mesenchymal stem cells efficacy in myocardial infarction therapy.Materials today. Bio · 2025Review
- Preclinical extracellular matrix-based treatment strategies for myocardial infarction: a systematic review and meta-analysis.Communications medicine · 2025Article
- From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence.Frontiers in bioengineering and biotechnology · 2025Review
- Generation of a Human Induced Pluripotent Stem Cell Line Expressing a Magnetic Resonance Imaging Reporter Gene.Small methods · 2024Article
- Hypothermic and cryogenic preservation of cardiac tissue-engineered constructs.Biomaterials science · 2024Article
- Stem cell-based therapies for heart failure management: a narrative review of current evidence and future perspectives.Heart failure reviews · 2024Review
- The immune regulatory role of exosomal miRNAs and their clinical application potential in heart failure.Frontiers in immunology · 2024Review
- Intramyocardial immunomodulation with human CD16Frontiers in cardiovascular medicine · 2024Article
- Advancing Spinal Cord Injury Treatment through Stem Cell Therapy: A Comprehensive Review of Cell Types, Challenges, and Emerging Technologies in Regenerative Medicine.International journal of molecular sciences · 2023Review
- Notch Pathways Regulate Expression of Angiostatic Factor Activin A in Endothelial-Pericyte-Like Mesenchymal Stromal Cell Interactions.Stem cells and development · 2023Article
- The Current Therapeutic Role of Chromatin Remodeling for the Prognosis and Treatment of Heart Failure.Biomedicines · 2023Review
- SDF-1α-Releasing Microspheres Effectively Extend Stem Cell Homing after Myocardial Infarction.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure continues to be one of the leading causes of morbidity and mortality worldwide. Myocardial infarction is the primary causative agent of chronic heart failure resulting in cardiomyocyte necrosis and the subsequent formation of fibrotic scar tissue. Current pharmacological and non-pharmacological therapies focus on managing symptoms of heart failure yet remain unable to reverse the underlying pathology. Heart transplantation usually cannot be relied on, as there is a major discrepancy between the availability of donors and recipients. As a result, heart failure carries a poor prognosis and high mortality rate. As the heart lacks significant endogenous regeneration potential, novel therapeutic approaches have incorporated the use of stem cells as a vehicle to treat heart failure as they possess the ability to self-renew and differentiate into multiple cell lineages and tissues. This review will discuss past, present, and future clinical trials, factors that influence stem cell therapy outcomes as well as ethical and safety considerations. Preclinical and clinical studies have shown a wide spectrum of outcomes when applying stem cells to improve cardiac function. This may reflect the infancy of clinical trials and the limited knowledge on the optimal cell type, dosing, route of administration, patient parameters and other important variables that contribute to successful stem cell therapy. Nonetheless, the field of stem cell therapeutics continues to advance at an unprecedented pace. We remain cautiously optimistic that stem cells will play a role in heart failure management in years to come.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.